Document is current
Any future updates will be listed below
-
Authors
Lotan, Yair
Anai, Satoshi
Kim, Howard
Gin, Greg
Akhavein, Arash
Miyake, Makito
Luu, Michael
Ahdoot, Michael
Messing, Edward
Peers, Garry
Chen, Andrew
Moradzadeh, Ariel
Chin, Arnold I.
Liu, Menghan
Tanaka, Sunao
Tikhonekov, Sergei
Pagano, Ian
Zheng, Yingye
Zhang, Zhen
Furuya, Hideki
Rosser, Charles J.
- License Information
-
More Information
Article History
Received: 6 March 2026
Accepted: 30 April 2026
First Online: 9 May 2026
Declarations
:
: Cedars Sinai Local ethics review board approved for all sites in the US (single IRB; Pro00057068), except Long Beach VA Healthcare System (IRB# 1737898) which had its own ethic review board approval. Nara Medical University (IRB# 2696) and Seiwa Medical Hospital (IRB# 206) ethics review board approved the study. Participants gave written informed consent.
: Not applicable.
: Not applicable.
: Dr. Charles Rosser is an officer of Nonagen Bioscience. Yair Lotan has consulted for Photocure, Astra-Zeneca, Merck, Fergene, Nucleix, Ambu, Seattle Genetics, virtuoso surgical, Stimit, Urogen, Vessi medical, CAPs medical, Nonagen, Aura Biosciences, Inc., Convergent Genomics, Pacific Edge, Pfizer, Phinomics Inc, CG oncology, Uroviu, Promis Diagnostics, Valar labs, Uroessentials, NRx Pharmaceuticals, Vesica health, Janssen, Immunity Bio, Trigone pharma, Relmada. All other authors declare that they have no competing interests.
